Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

  1. Home/
  2. Media Center/
  3. Press releases /
  4. Innovative Medicine

Innovative Medicine

Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. For The Oral Interlukin-23 Receptor Antagonist Drug Candidate For The Treatment of Inflammatory Bowel Disease

Long-standing relationship between Johnson & Johnson Innovation, Janssen and Protagonist Therapeutics leads to advancement of promising oral drug candidate for Crohn’s disease and ulcerative colitis

Real-World Evidence Shows Oral INVOKANA® 300 mg Demonstrates Comparable A1C Reduction and Control to Injectable GLP-1 Receptor Agonists

Patients Taking INVOKANA® 300 mg Were Significantly Less Likely to Discontinue the Medication or Be Prescribed a New Antihyperglycemic Agent

European Commission Extends Approval for Janssen’s DARZALEX®▼(daratumumab) to Include Multiple Myeloma Patients Who Have Received at Least One Prior Therapy

First-in-class CD38-directed monoclonal antibody now approved for use in combination with two standard of care regimens

Janssen Collaborates with Premier Inc. on Unique Study to Improve Stroke Risk Management among Hospitalized Patients with Atrial Fibrillation

The QUANTUM AF study will evaluate the impact of a hospital quality improvement program on the use of new guidelines to treat patients with atrial fibrillation (AF) at risk for ischemic stroke

Johnson & Johnson Innovation Launches Advancing the Safe Use of Healthcare Products QuickFire Challenge

Challenge awards up to $200,000 to novel solutions that advance safety by informing patients and consumers, simulating surgical procedures or ensuring proper storage and use of prescription, over-the-counter and cosmetic products